MCED Testing Enters New Diagnostic Realms
Elie Dolgin • August 4, 2023
Real-world performance data and trial results in symptomatic individuals continue to validate the promise of screening for multiple cancers with a single blood draw. However, some worry about the performance of GRAIL's commercially available multicancer early detection test in certain high-risk groups that were not the focus of early clinical development efforts.
Continue reading at Cancer Discovery.
With organoids, assembloids and a growing bioengineering toolkit, scientists are pushing the limits of human brain models.
Drug makers are scrambling to navigate an ‘existential threat’ to a once-celebrated technology.